Pharmacogenomics of acute leukemia

Pharmacogenomics

Volumn 8, Issue 7, 2007, Pages 817-834

  Ansari, Marc ^a   Krajinovic, Maja ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cancer; Chemotherapy; Genetic polymorphism; Leukemia; Outcome; Pharmacogenetics; Survival; Toxicity

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLIN D1; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GLUTATHIONE TRANSFERASE; MANGANESE SUPEROXIDE DISMUTASE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN; PREDNISONE; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW TOXICITY; CANCER MORTALITY; CANCER THERAPY; CAUSE OF DEATH; CHILD DEATH; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHARMACOGENOMICS; PROGNOSIS; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR CELL; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION;

ANTINEOPLASTIC AGENTS; CHILD; HUMANS; LEUKEMIA, MYELOID, ACUTE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 34548137731     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.7.817     Document Type: Review

References (130)

1. Bleyer WA: The impact of childhood cancer on the United States and the world. CA Cancer J. Clin. 6(40), 355-367 (1990).
2. Pui CH, Cheng C, Leung WA et al.: Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N. Engl. J. Med. 349(7), 640-649 (2003).
3. Relling MV, Hancock ML, Rivera GK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer. Inst. 23(91), 2001-2008 (1999).
4. Cheok MH, Evans WE: Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat. Rev. Cancer 2(6), 117-129 (2006).
5. Kager L, Evans WE: Pharmacogenomics of acute lymphoblastic leukemia. Curr. Opin. Hematol. 4(13), 260-265 (2006).
6. Wang L, Weinshilboum R: Thiopurine S-methyltransferase pharmacogenetics: insight, challenges and future directions. Oncogene 11(25), 1629-1638 (2006).
7. McLeod HL, Krynetski EY, Relling MV, Evans WE: Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 4(14), 567-572 (2000).
8. Stanulla M, Schaeffeler E, Flohr T et al.: Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 12(293), 1485-1489 (2005).
9. Lennard L, Richard S, Cartwright CS et al.: The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 4(80), 375-383 (2006).
10. Relling MV, Pui CH, Cheng C, Evans WE: Thiopurine methyltranferase acute lymphoblastic leukemia. Blood 2(107), 843-844 (2006).
11. Maitland ML, Vasisht K, Retain MJ: TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol. Sci. 8(27), 432-437 (2006).
12. Messmann R, Allegra C: Antifolates, In: Cancer, Chemotherapy and Biotherapy (Principles and Practice) Chabner BA, Longo DL (Eds). Lippincott, Williams & Wilkins, PA, USA (2001).
13. Calvert H: An ovierview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Semin. Oncol. 6(26 Suppl. 2), 3-10 (1999).
14. Chango A, Emery-Fillon N, de Courcy GP et al.: A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol. Genet. Metab. 4(70), 310-315 (2000).
15. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M: Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic laukemia. Blood 10(100), 3832-3834 (2002).
16. Whetstine JR, Gifford AJ, Witt T et al.: Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin. Cancer Res. 11(7), 3416-3422 (2001).
17. Kishi S, Cheng C, French D et al.: Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109(10), 4151-4157 (2007).
18. Shimasaki N, Mori T, Samejima H et al.: Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J. Pediatr. Hematol. Oncol. 2(28), 64-68 (2006).
19. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymophism of the tandemly repeated sequencing in the 5′-terminal regulatory rejon of the human gene for thymidylate synthase. Cell Struct. Funct. 3(20), 191-197 (1995).
20. Mandola MV, Stoehlmacher J, Muller-Weeks S et al.: A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 11(63), 2898-2904 (2003).
21. Pullmann R Jr, Abdelmohsen K, Lal A et al.: Differential stability of thymidylate synthase 3′-untranslated region polymorphism variants regulated by AUF1. J. Biol. Chem. 33(281), 23456-23463 (2006).
22. Krajinovic M, Costea I, Chiasson S: polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 9311(359), 1033-1034 (2002).
23. Krajinovic M, Costea I, Primeau M, Dulucq S, Moghrabi A: Combining several polymorphisms of the thymidylate synthase gene for pharmacogenetic analysis Pharmacogenomics J. 6(5), 374-380 (2005).
24. Rocha JC, Cheng C, Liu W et al.: pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 12(105), 4752-4758 (2005).
25. Relling MV, Yang W, Das S et al.: Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J. Clin. Oncol. 19(22), 3930-3936 (2004).
26. Costea I, Moghrabi A, Laverdiere C, Graziani A, Krajinovic M: Folate cycle gene variant and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 8(91), 1113-1116 (2006).
27. Schwahn B, Rozen R: Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am. J. Pharmacogenomics 3(1), 189-201 (2001).
28. Krajinovic M, Moghrabi A: Pharmacogenetics of methotrexate. Pharmacogenomics 7(5), 819-835 (2004).
29. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI: Efffect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J. Natl Cancer Inst. 2(96), 134-144 (2004).
30. Krajinovic M, Lemieux-Blanchard E, Chiasson S et al.: Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 1(4), 66-72. (2004).
31. Aplenc R, Thompson J, Han P et al.: Methylenetetrahydrofolate reductase polymorphism and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 6(65), 2482-2487 (2005).
32. Kishi S, Griener J, Cheng C et al.: Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J. Clin. Oncol. 16(21), 3084-3091 (2003).
33. Chiusolo P, Reddiconto G, Casoreli I et al.: Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann. Oncol. 12(13), 1915-1918 (2002).
34. Li W, Fan J, Hochhauser D et al.: Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc. Natl Acad. Sci. USA 22(92), 10436-10440 (1995).
35. Hochhauser D, Schnieders B, Ercikan-Abali E et al.: Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J. Natl Cancer Inst. 18(88), 1269-1775 (1996).
36. Hochhauser D: Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer. Anticancer Drug 10(8), 903-910 (1997).
37. Hosokawa Y, Tu T, Tahara H, Smith AP, Arnold A: Absence of cyclin D1/ PRAD1 point mutations in human breast cancers and perathyroid adenomas and identification of a new cyclin D1 gene polymorphism. Cancar Lett. 2(93), 165-170 (1995).
38. Betticher DC, Thatcher N, Altermatt HJ et al.: Alternate splicing produces novel cyclin D1 transcript. Oncogene 5(11), 1005-1011 (1995).
39. Burd CJ, Petre CE, Morey LM et al.: Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc. Natl Acad. Sci. USA 7(103), 2190-2195 (2006).
40. Hou X, Wang S, Zhou Y et al.: Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Int. J. Hematol. 3(82), 206-209 (2005).
41. Costea I, Moghrabi A, Krajinovic M: The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics 9(13), 577-580 (2003).
42. Longo GS, Gorlick R, Tong WP et al.: γ-glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Oncol. Res 5(9), 259-263 (1997).
43. Rhee MS, Wang Y, Nair MG, Galivan J: Acquisition of resistance to antifolates caused by enhanced γ-glutamyl hydrolase activity. Cancer Res 10(53 Suppl.). 2227-2230 (1993).
44. Longo GS, Gorlick R, Tong WP, Ercikan E, Bertino JR: Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. Blood 3(90), 1241-1245 (1997).
45. Chave KJ, Ryan TJ, Chmura SE, Galiva J: Identification of single nucleotide polymorphisms in the human γ-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene 319, 167-175 (2003).
46. Masson E, Relling MV, Synold TW et al.: Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J. Clin. Invest. 1(97), 73-80 (1996).
47. Dervieux T, Kremer J, Lein DO et al..: Contribution of common polymorphisms in reduced folate carrier and γ-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 11(14), 773-739 (2004).
48. Cheng Q, Wu B, Kager L et al.: A substrate specific functional polymorphism of human γ-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics 8(14), 557-567 (2004).
49. Garcia-Borunissen F, Moghrabi A, Krajinovic M: Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of γ-glutamyl hydrolase (GGH) gene. Leuk. Res 31(7), 1023-1025. (2007).
50. Cheng Q, Cheng C, Crews KR et al.: Epigenetic regulation of human γ-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. Am. J. Hum. Genet. 2(79), 264-274 (2006).
51. Kaspers GJ, Pieters R, van Zantwijk CH et al.: Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and crosss-resistance to other drugs. Blood 1(92), 259-266 (1998).
52. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R: In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 8(89), 2959-2965 (1997).
53. Kaspers GJ, Veerman AJ, Pieters R et al.: In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 7(90), 2723-2729 (1997).
54. Gaynon PS, Carrel AL: Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv. Exp. Med. Biol. 457, 593-605 (1999).
55. Kofler R: The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells. Histochem. Cell. Biol. 1(114), 1-7 (2000).
56. Felner EI, Thompson MT, Ratliff AF, White PC, Dickson BA: Time course of recovery of adrenal function in children treated for leukemia. J. Pediatr. 1(137), 21-24 (2000).
57. Waber DP, Carpentieri SC, Klar N et al.: Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J. Pediatr. Hematol. Oncol. 3(22), 206-213 (2000).
58. Mattano LA Jr, Sather HN, Trigg ME, Nachman JB: Osteonecrosis as a complicatin of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J. Clin. Oncol. 18(18), 3262-3272 (2000).
59. Barr RD, Atkinson SA, Halton JM: Bone mineral density in survivors of cancer in childhood. J. Pediatr. Hematol. Oncol. 3(21), 249-250 (1999).
60. Tissing WJ, Meijerink JP, den Boer ML, Pieters R: Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia 1(17), 17-25 (2003).
61. Tissing WJ, Lauten M, Meijerink JP et al.: Expression of the glucorticoid receptor and its isoforms in relation to glucocorticoid resistance in childhood acute lymphocytic leukemia. Haematologica 9(90), 1279-1281 (2005).
62. van Rossum EF, Koper JW, Huizenga NA et al.: A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes 10(51), 3128-3134 (2002).
63. van Rossum EF, Koper JW, van den Beld AW et al.: Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin. Endocrinol. (Oxf.) 5(59), 585-592 (2003).
64. Fleury I, Primeau M, Doreaua A et al.: Polymorphisms in genes involved in the corticosteroid response and the outcome of childhood acute lymphoblastic leukemia. Am. J. Pharmacogenomics 5(4), 331-341 (2004).
65. Panarelli M, Holloway CD, Fraser R et al.: Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects. J. Clin. Endocrinol. Metab. 6(83), 1846-1852 (1998).
66. Stevens A, Ray DW, Zeggini E et al.: Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. J. Clin. Endocrinol. Metab. 2(89), 892-897 (2004).
67. Tissing WJ, Meijerink JP, den Boer ML et al.: Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia. Clin. Cancer Res. 16(11), 6050-6056 (2005).
68. Franchimont D, Martens H, Hagelstein MT et al.: Tumor necrosis factor-α decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J. Clin. Endocrinol. Mietab. 8(84) 2834-2839 (1999).
69. Khatri VP, Caligiuri MA: A review of the association between interleukin-10 and human B-cell malignancies. Cancer Immunol. Immunother. 5(46), 239-244 (1998).
70. Lauten M, Matthias T, Stanulla M et al.: Association of initial response to prednisone treatment in childhood acute lymphoblastic leukemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia 8(16), 1437-1442 (2002).
71. Hartmann BL, Geley S, Loffer M et al.: Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis. Oncogene 3(18), 713-719 (1999).
72. Holleman A, Cheok MH, den Boer ML et al.: Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 6(351), 533-542 (2004).
73. Wei G, Twomey D, Lamb J et al.: Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 4(10), 331-342 (2006).
74. Den Boer ML, Kapaun P, Pieters R et al.: Myeloid antigen co-expression in childhood acute lymphoblastic leukemia: relationship with in vitro drug resistance. Br. J. Haematol. 4(105), 876-882 (1999).
75. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J: Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase π gene variants. Evidence for differential catalytic activity of the encoded proteins. J. Biol. Chem. 15(272), 10004-10012 (1997).
76. Stanulla M, Schrappe M, Brechlin AM, Zimmerman M, Welte K: Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 4(95), 1222-1228 (2000).
77. Anderer G, Schrappe M, Brechlin AM et al.: Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukemia. Pharmacogenetics 8(10), 715-726 (2000).
78. Meissner B, Stanulla M, Ludwig WD et al.: The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leukemia. Leukemia 11(8), 1920-1923 (2004).
79. Davies SM, Bhatia S, Ross JA et al.: Glutathione S-transferase genotypes, genetic suceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 1(100), 67-71 (2002).
80. Krajinovic M, Labuda D, Mathonnet G et al.: Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin. Cancre Res. 3(8), 802-810 (2002).
81. Takanashi M, Morimoto A, Yagi T et al.: Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia. Haematologica 11(88), 1238-1244 (2003).
82. Stanulla M, Schaffeler E, Arens S et al.: GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int. J. Hematol. 1(81), 39-44 (2005).
83. Kishi S, Yang W, Boureau B et al.: Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 1(103), 67-72 (2004)
84. Rodriquez-Antona C, Ingelman-Sundberg M: Cytochrome P450 pharmacogenetics and cancer. Oncogene 11(25), 1679-1691 (2006).
85. Celander M, Hahn ME, Stegeman JJ: Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. Arch. Biochem. Biophys. 1(329), 113-122 (1996).
86. Celander M, Weisbord R, Stegeman JJ: Glucocorticoid potentiation of cytochrome P4501A1 induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin in porcine and human endothelial cells in culture. Biochem. Biophys. Res. Commun. 3(232), 749-753 (1997).
87. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 4(27), 383-391 (2001).
88. Aplenc R, Glatfelter W, Han P et al.: CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukemia. Br. J. Haematol. 2(122), 240-244 (2003).
89. Powis G: Free radical formation by antitumor quinones. Free Radic. Biol. Med. 1(6), 63-101 (1989).
90. Bradshaw DW, Arceci RJ: Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol. 11(16), 3674-3690 (1998).
91. Gollapud S, Gupta S: Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival. J. Clin. Immunol. 6(21), 420-430 (2001).
92. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 7(97), 3473-3478 (2000).
93. Kim RB, Leake BF, Choo EF et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2(70), 189-199 (2001).
94. Salama NN, Yang Z, Bui T, Ho RJ: MDR1 haplotypes significantly minimize intacellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J. Pharm. Sci. 10(95), 2293-2308 (2006).
95. Kimchi-Sarfaty C, Oh JM, Kim IW et al.: A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 5811(315), 525-528 (2007).
96. Jamroziak K, Mlynarski W, Balcerczak E et al.: Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol. 5(72), 314-321 (2004).
97. Jamroziak K, Balcerczak E, Cebula B et al.: Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. Pharmacol. Rep. 6(57), 822-888 (2005).
98. Assaraf YG: Molecular basis of antifolate resistance. Cancer Metastasis Rev. 1(26), 153-181 (2007).
99. Hooijberg JH, Brosterman HJ, Kool M et al.: Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 11(59), 2532-2535 (1999).
100. Rau T, Erney B, Gores R et al.: High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphism on plasma concentrations. Clin. Pharmacol. Ther. 5(80), 468-476 (2006).
101. Haenisch S, Zimmerman U, Dazert E et al.: Influence of polymorphism of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 1(7), 56-65 (2007).
102. Balis FM, Holcenberg JS, Poplack DG et al.: Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood 10(92), 3569-3577 (1998).
103. Wall AM, Gajjar A, Link A et al.: Individualized methotrexate dosing in children with relapse acute lymphoblastic leukemia. Leukemia 2(14), 221-225 (2000).
104. Illmer T, Schuler US, Thiede C et al.: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 17(62), 4955-4692 (2002).
105. Kim DH, Park JY, Sohn SK et al.: Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int. J. Cancer 9(118), 2195-2201 (2006).
106. van der Holt B, van den Heuvel-Eibrink MM, van Schaik RH et al.: ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin. Pharmacol. Ther. 5(80), 427-439 (2006).
107. Weinshilboum R: Inheritance and drug response. N. Engl. J. Med. 6(348), 529-537 (2003).
108. Davies SM, Robison LL, Buckley JD et al.: Glutathione S-transferase polymorphiss and outcome of chemotherapy in childhood acute myeloid leukemia. J. Clin. Oncol. 5(19), 1279-1287 (2001).
109. Voso MT, D'Alo F, Putzulu R et al.: Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 8(100), 2703-2707 (2002).
110. Barragan E, Collado M, Cervera J et al.: The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leuk. Res. 17118447 (2006).
111. Naoe T, Tagawa Y, Kiyoi H et al.: Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increase early death after chemotherapy. Leukemia 2(16), 203-208 (2002).
112. Weiss JR, Kopecky KJ, Godwin J et al.: Glutathione S-transferase (TSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials. Leukemia 12(20), 2169-2171 (2006).
113. Monzo M, Brunet S, Urbano-Ispizua A et al.: Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 12(107), 4871-4879 (2006).
114. Vosco MT, D'Alo F, Gumiero D et al.: The CYP1A*2a allele is an indepedent prognostic factor for acute myeloid leukemia. Haematologica 7(9), 982-984 (2005).
115. Sinha BK, Mimnaugh EG: Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytoxicity and resistance by certain tumors. Free Radoc. Biol. Med. 6(8), 567-581 (1990).
116. Koistinen P, Ruuska S, Saily M et al.: An association between manganese superoxide dismutase polymorphism and outcome of chemotherapy in acut myeloid leukemia. Haematologica 6(91), 829-832 (2006).
117. Chaney SG, Sancar A: DNA repair: enzymatic mechanisms and relevance to drug response. J. Natl. Cancer Inst. 19(88), 1346-1360 (1996).
118. Rajewsky MF, Engelbergs J, Thomale J, Schweer T: DNA repair: counteragent in mutagenesis and carcinogenesis - accomplice in cancer therapy resistance. Mutat. Res. 2-3(462), 101-105 (2000).
119. Allan JM, Smith AG, Wheatley K et al.: Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 13(104), 3872-3877 (2004).
120. Kuptsova N, Kopecky KJ, Godwin J et al.: Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood 9(109), 3936-3944 (2007).
121. Mehta PA, Alonso TA, Gerbing RB et al.: XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report. Blood 1(107), 39-45 (2006).
122. Lehrnbecher T, Bernig T, Hanisch M et al.: Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 10(19), 1745-1750 (2005).
123. Guo Y, Shafer S, Weller P, Usuka J, Peltz G: Pharmacogenomics and drug development. Pharmacogenomics 8(6), 857-864 (2005).
124. van den Akker, van Marle ME, Gurwitz D et al.: Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopourine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 5(7), 783-792 (2006).
125. Cheng Q, Yang W, Raimondi SC et al.: Karyotypic abnormalities create disordance of germline genotype and cancer cell phenotypes. Nat. Genet. 8(37), 878-882 (2005).
126. Cheok MH, Lugthart S, Evans WE: Pharmacogenomics of acute leukemia. Annu. Rev. Pharmacol. Toxicol. 46, 317-353 (2006).
127. Yagi T, Morimoto A, Eguchi M et al.: Indentification of a gene expression signature associated with pediatric AML prognosis. Blood 5(102), 1849-1856 (2003).
128. Evans WE, Guy RK: Gene expression as a drug discovery tool. Nat. Genet. 3(36), 214-215 (2004).
129. Sachidanandam R, Weissman D, Schmidt SC et al.: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 6822(409), 928-933 (2001).
130. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE: Prognostic importance of 6-mercaptopurine dose intesity in acute lymphoblastic leukemia. Blood 9(93), 2817-2823 (1999).